Cardiac Affection in Type 1 Diabetic Patients in Relation to Omentin
Dayem SM., Battah AA., Shehaby AE.
Prospective Study on Type 1 Diabetes, Cardiovascular Disease, published in Open Access Maced J Med Sci (2015) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Open Access Maced J Med Sci (2015)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 27275311
- PMCID
- PMC4877911
- DOI
- 10.3889/oamjms.2015.132
- Citations
- 5
Abstract (original English)
Aim To evaluate cardiac affection in type 1 diabetes in relation to Omentin. Patients and methods Sixty two diabetics and 30 volunteer of the same age and sex were included as a control group. Blood sample was taken for assessment of omentin and oxidized low density lipoprotein (OxLDL), glycosylated hemoglobin (HbA1) and lipid profile. Urine sample was taken for assessment of albumin/creatinine ratio. 24 hour holter was also done. T-test, simple correlation followed by stepwise multiple regression analysis was used for analysis of data. Results Parameters of 24 hour holter were significantly lower in diabetics. Omentin was significantly lower, while OxLDL were significantly higher than controls. RMSSD, ST deviation and OxLDL were the parameters related to omentin by stepwise multiple regression analysis in diabetics. Conclusion Diabetic patients had a cardiac autonomic neuropathy. A significant reduction of omentin and elevation OxLDL imply that they influence glucose metabolism in type 1 diabetes. Omentin had a significant relation to 24 hr holter which may reflect its role in cardiac affection. Omentin and OxLDL had a role in renal affection.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Transforming hypoglycemia prediction in adult type 1 diabetes: a systematic review and meta-analysis for precision care
Meta-analysis on Type 1 Diabetes, published in Open Life Sci (2026) — summary generated from the PubMed abstract.
- 2026
Open Life Sci - Level ASystematic ReviewEurope PMC
Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review
Systematic Review on Type 1 Diabetes, published in Front Transplant (2025) — summary generated from the PubMed abstract.
- 2025
Front Transplant - Level AMeta-analysisEurope PMC
Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis
Meta-analysis on Type 1 Diabetes, published in J Diabetes Res (2020) — summary generated from the PubMed abstract.
- 2020
J Diabetes Res7 citations - Level AMeta-analysisEurope PMC
Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits
Meta-analysis on Type 1 Diabetes, Type 2 Diabetes, published in Stem Cell Investig (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cell Investig22 citations - Level AMeta-analysisEurope PMC
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis
Meta-analysis with a reported sample of 524 on Type 1 Diabetes, published in PLoS One (2016) — summary generated from the PubMed abstract.
- 2016
- n = 524
PLoS One81 citations - Level BClinical TrialEurope PMC
Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Clinical Trial on Type 1 Diabetes, Type 2 Diabetes, Scar, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells1 citations